Natera, Inc. (NASDAQ:NTRA) President of Clinical Diagnostics, Solomon Moshkevich, has sold shares worth over $63,000, according to a recent filing with the Securities and Exchange Commission. The transaction, which took place on March 28, 2024, involved the sale of 707 shares of common stock at a price of $90.4158 each.
The sale was conducted to meet tax withholding and remittance obligations related to the vesting of Restricted Stock Units (RSUs). The shares were sold pursuant to a pre-arranged 10b5-1 trading plan, which allows company insiders to sell stocks at predetermined times to avoid accusations of insider trading.
Following the transaction, Moshkevich still holds 197,560 shares of Natera, Inc. The company, headquartered in Austin, Texas, specializes in medical laboratory services and is known for its advanced genetic testing and diagnostics.
Investors often monitor insider transactions as they can provide insights into a company's financial health and future prospects. The sale by Moshkevich represents a notable insider trading event, given his position within the company and the value of the shares sold. However, it's important to note that the use of a 10b5-1 plan suggests that the sale was planned in advance and not based on any recent or upcoming material information that could affect Natera's stock price.
InvestingPro Insights
As Natera, Inc. (NASDAQ:NTRA) sees insider trading activity, it's beneficial for investors to consider the broader financial landscape of the company. According to InvestingPro, Natera has been experiencing significant price movements in the market. The company's stock has surged with a 110.08% return over the last six months and continues to trade near its 52-week high, with the price at 96.59% of this peak. This uptick could reflect investor optimism about the company's prospects or a broader market trend.
Despite this positive price performance, InvestingPro Tips suggest that the stock is currently in overbought territory based on the Relative Strength Index (RSI), which could indicate a potential pullback. Moreover, analysts are not expecting the company to be profitable this year, as reflected in the negative P/E ratios, with the latest adjusted P/E for the last twelve months as of Q4 2023 standing at -25.82. These metrics suggest that while the stock has performed well in terms of price, the underlying financials may present a different picture.
Investors interested in a deeper analysis of Natera can find additional insights on InvestingPro, which offers a comprehensive suite of data and analytics. There are currently 13 more InvestingPro Tips available for Natera, providing a more detailed look at aspects such as debt levels, profitability, and liquidity. To access these tips and enhance your investment strategy, use the coupon code PRONEWS24 for an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.